{"id":2966,"date":"2026-07-09T16:43:53","date_gmt":"2026-07-09T16:43:53","guid":{"rendered":"https:\/\/retrotradingreport.com\/index.php\/2026\/07\/09\/why-this-biotech-stock-more-than-tripled-on-thursday\/"},"modified":"2026-07-09T16:43:53","modified_gmt":"2026-07-09T16:43:53","slug":"why-this-biotech-stock-more-than-tripled-on-thursday","status":"publish","type":"post","link":"https:\/\/retrotradingreport.com\/index.php\/2026\/07\/09\/why-this-biotech-stock-more-than-tripled-on-thursday\/","title":{"rendered":"Why this biotech stock more than tripled on Thursday"},"content":{"rendered":"
<\/div>\n

Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough.<\/p>\n

In a press release dated July 9th<\/sup>, the company said its UK subsidiary signed an \u201cexclusive\u201d multi-country commercial supply agreement with Fosun Diagnostics, a key division of Shanghai Fosun Pharmaceutical.<\/p>\n

Despite the cosmic run today, Virax stock remains down some 10% year-to-date.<\/p>\n

A sneak peek into the Fosun deal<\/h2>\n

Under the terms of the agreement, Virax will supply its ImmuneSelect product line across six major ASEAN markets: Thailand, Vietnam, Indonesia, Singapore, Malaysia, and the Philippines.<\/p>\n

Note that the company\u2019s ImmuneSelect includes specialized ELISpot assay plates used for cellular immune response profiling.<\/p>\n

VRAX shares soared this morning primarily because, unlike typical biotech milestones that rely on multi-year clinical trial horizons, this deal sets up an immediate framework for product supply via direct purchase orders.<\/p>\n

The commercial rollout is fast-tracked to start in Thailand, specifically targeting near-term client demand for tuberculosis-related research applications.<\/p>\n

Adding to momentum on Thursday is algorithmic buying as Virax Biolabs ripped through its major moving averages (MAs), indicating shifting momentum in favour of the bulls.<\/p>\n

Why are VRAX shares soaring aggressively today<\/h2>\n

Virax Biolabs is a micro-cap biotechnology company<\/a> that brought in under $1 million in revenue over the past year.<\/p>\n

Partnering with a powerhouse like \u201cFosun\u201d instantly grants them access to an established regional commercial infrastructure and expansive customer network they couldn\u2019t have built independently.<\/p>\n

Investors should also note that VRAX stock has a tight float coming off a recent \u201c1-for-25\u201d reverse split \u2013 executed to regain compliance with Nasdaq\u2019s minimum bid requirements.<\/p>\n

When a fundamental, revenue-generating catalyst like this hits a low-float micro-cap stock, it often sparks a massive volume squeeze, which is exactly why trading volume blew past 57 million shares today compared to its usual 1-million daily average.<\/p>\n

Should you chase the momentum in Virax stock?<\/h2>\n

Disciplined investors should still practice extreme caution before chasing Virax shares at these stretched levels.<\/p>\n

Despite today\u2019s fundamental catalyst, the biotech firm remains a super speculative microcap penny stock with a history of severe revenue constraints and net losses.<\/p>\n

Because of its tight post-split float, VRAX is highly vulnerable to extreme volatility, algorithmic momentum traps, and pump-and-dump dynamics where early momentum buyers eventually dump shares on retail investors.<\/p>\n

Moreover, micro-cap companies experiencing sudden volume surges often capitalize on the rally by launching dilutive secondary share offerings to raise capital as well. So dilution remains a near-term risk as well.<\/p>\n

All in all, until this cross-border deal translates into sustained, multi-quarter sales growth on the balance sheet, chasing today\u2019s vertical spike carries a high risk of severe capital impairment.<\/p>\n

That said, the only Wall Street analyst that currently covers Virax Biolabs has a \u201cBuy\u201d ratin<\/a>g<\/a> on it<\/a>, with the mean price target set at a rather bullish $25.<\/p>\n

The post Why this biotech stock more than tripled on Thursday<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough.In a press release dated July 9th, the company said its UK subsidiary signed an \u201cexclusive\u201d multi-country commercial supply agreement with Fosun Diagnostics, a key division of Shanghai Fosun Pharmaceutical.Despite the cosmic run today, Virax stock remains down some…<\/p>\n","protected":false},"author":1,"featured_media":2967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing"],"_links":{"self":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts\/2966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/comments?post=2966"}],"version-history":[{"count":0,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/posts\/2966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/media\/2967"}],"wp:attachment":[{"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/media?parent=2966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/categories?post=2966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retrotradingreport.com\/index.php\/wp-json\/wp\/v2\/tags?post=2966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}